Antibiotic activity of telithromycin and comparators against bacterial pathogens isolated from 3,043 patients with acute exacerbation of chronic bronchitis by Sethi, Sanjay et al.
BioMed  Central
Page 1 of 7
(page number not for citation purposes)
Annals of Clinical Microbiology and 
Antimicrobials
Open Access Research
Antibiotic activity of telithromycin and comparators against 
bacterial pathogens isolated from 3,043 patients with acute 
exacerbation of chronic bronchitis
Sanjay Sethi*1, Antonio Anzueto2 and David J Farrell3
Address: 1University at Buffalo SUNY, Buffalo NY, USA, 2South Texas Veterans Health Care System, Audie L. Murphy Memorial Veterans Hospital 
Division, San Antonio, USA and 3GR Micro Limited, London, UK
Email: Sanjay Sethi* - ssethi@buffalo.edu; Antonio Anzueto - anzueto@uthscsa.edu; David J Farrell - d.farrell@grmicro.co.uk
* Corresponding author    
Abstract
Background:  Antimicrobial therapy is considered an important component in the medical
management of most patients with acute exacerbation of chronic bronchitis (AECB). The three
predominant bacterial species isolated are nontypeable Haemophilus influenzae,  Moraxella
catarrhalis, and Streptococcus pneumoniae. Staphylococcus aureus is also frequently isolated while
atypical bacteria are thought to cause up to 10% of exacerbations. Antibacterial resistance is
increasing worldwide and little surveillance data exist concerning pathogens isolated from patients
with AECB.
Methods: This study examines the prevalence of antibacterial resistance in isolates obtained from
patients with clinically diagnosed AECB. A total of 3043 isolates were obtained from 85 centres in
29 countries, between 1999–2003, and were tested against the new ketolide telithromycin and a
panel of commonly used antibiotics.
Results and Discussion: Of the S. pneumoniae isolates, 99.9% were susceptible to telithromycin,
but only 71% were susceptible to erythromycin and 75.3% to penicillin. Of the H. influenzae isolates,
99.6% were susceptible to telithromycin. 11.7% of these isolates produced β -lactamase. Almost
10% of S. pneumoniae were multidrug-resistant; 99.0% of these isolates were susceptible to
telithromycin. Telithromycin also demonstrated good in vitro activity against M. catarrhalis (MIC90 =
0.12 mg/L) and was the most active compound against methicillin-susceptible S. aureus (98.9%
susceptible).
Conclusion: Telithromycin demonstrated similar or better activity against the bacterial species
investigated than the other agents, with the most complete coverage overall. These species are the
predominant causative bacterial pathogens in AECB and thus the spectrum of activity of
telithromycin makes it a potential alternative for the empirical treatment of AECB.
Introduction
The World Health Organization (WHO) estimates that
chronic obstructive pulmonary disease (COPD) is the
fourth leading cause of death worldwide. In the year 2000,
it was estimated that 2.74 million people died from
COPD worldwide [1]. COPD is defined by the presence of
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irreversible or partially irreversible airway obstruction in
patients with chronic bronchitis or emphysema [2,3]. The
disease is characterized by recurrent (1–4 per year) acute
exacerbations of chronic bronchitis (AECB), defined by a
subjective increase from baseline of one or more symp-
toms including shortness of breath, cough, sputum pro-
duction, and sputum purulence [4]. The precipitating
factors for AECB have been extensively researched and
determined to be heterogeneous with complex aetiology
[5-10].
Results from a number of placebo-controlled clinical
investigations have demonstrated that antibacterial agents
are of significant clinical benefit in the treatment of AECB,
particularly for those patients with at least two of the three
cardinal symptoms of AECB (worsening dyspnoea,
increased sputum volume, and increased sputum puru-
lence) and/or severe airway obstruction [11-13]. Other
clinical trials measuring non-traditional endpoints have
shown that antibiotic therapy reduces the time to symp-
tom resolution and has long-term benefits including
greater intervals between episodes of exacerbation
[14,15]. Consequently, antibiotic therapy is considered
an important component in the medical management of
patients with AECB.
Bacteria can be isolated from 40–60% of sputum samples
of patients experiencing AECB [16]. The three predomi-
nant bacterial species isolated are non-typeable Haemo-
philus influenzae,  Moraxella catarrhalis, and Streptococcus
pneumoniae. Other less frequently isolated potential path-
ogens are Gram-negative enterobacteria, Haemophilus
parainfluenzae, Staphylococcus aureus, and Pseudomonas aer-
uginosa. Gram negative enterobacteria and Pseudomonas
aeruginosa are more frequently isolated in patients with
severe underlying disease [10]. Viral infections are present
in approximately 30% of exacerbations, Mycoplasma pneu-
moniae in 1–10%, and Chlamydophila pneumoniae in 4–5%
(serologically identified) [6-10].
Amoxycillin, ampicillin, sulfamethoxazole-trimethoprim
(trimethoprim-sulphamethoxazole), tetracyclines, and
erythromycin are considered first-line antimicrobial ther-
apy for AECB [17]. The clinical utility of these agents is,
however, being hampered by the increasing global spread
of pathogens with resistance to one or more of these
agents. Up to 40% of H. influenzae isolates and more than
90% of M. catarrhalis isolates produce β -lactamase and
this limits the value of penicillins and some other β -
lactams [18]. Furthermore, resistance to penicillin and
macrolides has spread rapidly among isolates of S. pneu-
moniae [19]. Other agents used include extended spectrum
cephalosporins, amoxycillin/clavulanate, azithromycin,
clarithromycin, and levofloxacin.
Telithromycin is the first ketolide available for clinical
use. Derivatives of erythromycin-A, the ketolides, like the
macrolides, exert their antimicrobial action by binding to
the bacterial ribosome. Although both macrolides and
ketolides bind strongly to a region of domain V in the 23S
rRNA of the ribosome, telithromycin has additional
strong binding to a region in domain II to which the mac-
rolides bind weakly [20]. Ketolides are also poor sub-
strates for the efflux pump (mefA) responsible for
macrolide resistance in S. pneumoniae [21]. Consequently,
telithromycin has been found to have potent activity
against macrolide resistant S. pneumoniae with methylase,
efflux or ribosomal mutations as the mechanisms of
resistance [22,23].
There is a need for alterative therapeutic options for the
treatment of AECB and surveillance data are needed to
help determine the suitability of new agents. The PRO-
TEKT (Prospective Resistant Organism Tracking and Epi-
demiology for the Ketolide Telithromycin) study is an
international, longitudinal, antibacterial resistance sur-
veillance study, which was initiated in 1999 to monitor
the spread of resistance among respiratory tract pathogens
worldwide. Here we analyze the in vitro antimicrobial
activity of bacterial isolates obtained from patients clini-
cally diagnosed with AECB in 3 consecutive years of the
PROTEKT study. Using these data, and previously pub-
lished clinical data, the potential role of telithromycin in
the treatment of AECB will be discussed.
Materials and Methods
Patients and bacterial isolates
Details of the study design, including the selection of
patients and the methodology for the identification of iso-
lates and their storage in the PROTEKT study has been
described previously [24]. Isolates in this study were
obtained from patients diagnosed with AECB from in 85
centres in 29 countries (Table 1). To be included in this
analysis, an isolate was deemed pathogenic in AECB by
clinical and laboratory findings. Isolates were only accept-
able if the patient was ≥  30 years old and the specimen
Table 1: Geographical distribution of isolates from AECB 
patients used in this study
Area Countries Centres Isolates
North America 2 4 319
South America 6 14 427
Europe 13 41 1847
Australasia 6 19 437
South Africa 1 6 13
Totals 29 85 3043Annals of Clinical Microbiology and Antimicrobials 2005, 4:5 http://www.ann-clinmicrob.com/content/4/1/5
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was obtained from blood, bronchoalveolar lavage (BAL),
or sputum. Isolates from patients diagnosed with AECB
obtained from other sites (e.g., ear, throat, nasopharynx)
and isolates obtained from patients <30 years of age were
excluded from this analysis because AECB is more likely to
be present in patients ≥  30 years of age and the responsi-
ble bacterial pathogen is more likely to be correctly iso-
lated from the blood, BAL, or sputum.
In Year 1 (1999–2000), each centre had a quota of 60 iso-
lates of S. pneumoniae, 40 H. influenzae, 15 H. parainfluen-
zae, 20 M. catarrhalis, 25 Streptococcus pyogenes and 20 S.
aureus to collect. In years 2 (2000–2001) and 3 (2001–
2002), H. parainfluenzae were not collected and 15 extra
isolates of S. pneumoniae were collected instead.
Antimicrobial testing
The comparator agents used were four β -lactams; penicil-
lin (for S. pneumoniae and S. aureus), ampicillin (for H.
influenzae, H. parainfluenzae and M. catarrhalis), amoxycil-
lin/clavulanate, and cefuroxime, three macrolides/azali-
des; erythromycin, clarithromycin, and azithromycin, the
folate synthesis inhibitor; trimethoprim-sulphamethoxa-
zole, the tetracycline; tetracycline and a fluoroquinolone,
levofloxacin.
Minimum inhibitory concentrations (MIC) of each anti-
bacterial were determined using the National Committee
for Clinical and Laboratory Standards (NCCLS) broth
microdilution methodology and lyophilised microtitre
plates (Sensititre, Trek Diagnostics) at a central laboratory
(GR Micro Ltd., London, UK) [26]. NCCLS breakpoints
[25,26] were used to interpret the MIC data and to deter-
mine susceptibility status. The NCCLS breakpoints for tel-
ithromycin for S. pneumoniae and for S. aureus are ≤  1 mg/
l is susceptible, 2 mg/l is intermediate, and ≥  4 mg/l is
resistant, and for H. influenzae ≤  4 mg/l is susceptible, 8
mg/l is intermediate, and ≥  16 mg/l is resistant [27].
Results
A total of 3043 bacterial pathogens were isolated from
patients in 29 countries around the world, with by far the
largest number of specimens (1841, 60.5%) coming from
Europe (Table 1). Percentage of isolates by country were
as follows: Argentina 8.0%, Australia 1.1%, Austria 0.6%,
Brazil 4.0%, Canada 9.1%, China 1.7%, Colombia 0.1%,
Ecuador 0.6%, Eire 0.03%, France 3.4%, Germany 14.3%,
Hungary 1.2%, Indonesia 0.03%, Italy 18.9%, Japan
10.0%, Mexico 1.3%, Poland 10.2%, Portugal 2.8%, Rus-
sia 0.2%, South Africa 0.4%, South Korea 0.9%, Spain
5.3%, Sweden 0.4%, Switzerland 0.6%, Taiwan 0.7%,
Turkey 0.3%, United Kingdom 2.4%, United States 1.4%,
Venezuela 0.1%.
Of these isolates identified as causative pathogens for bac-
terial AECB, S. pneumoniae and H. influenzae formed the
majority (1075 and 1037 respectively), followed by M.
catarrhalis (536) (Table 2). Patients were predominantly
male (63.5%), with 47.5% of patients belonging to the
(30–64) year age group and 52.5% in the >64 year old age
group. No difference in the distribution of pathogens by
age group was observed (data not shown).
Table 3 shows the range of MIC values, the MIC50 and
MIC90 of the various agents against the five species. Where
breakpoints were available the percentage of isolates to
the various agents is also included. Telithromycin had
similar or better in vitro susceptibility than the comparator
agents against all of these species. Activity against S. pneu-
moniae was particularly good, with telithromycin being
the most active agent; 99.9% of isolates were classified as
susceptible and the MIC90 (0.12 mg/L) was substantially
lower than all other compounds tested.
One hundred and three (9.6%) S. pneumoniae isolates
(from 51 and 53 patients in the 30–64 and >64 year old
age groups respectively)) were resistant to both penicillin
(MIC ≥  2 mg/L) and erythromycin (MIC ≥  1 mg/L) and
this was reflected in resistance to amoxycillin, cefuroxime,
clarithromycin and azithromycin also (Table 4). These
isolates were found in 35 centres in 16 countries. Sixty of
these resistant isolates were also resistant to both trimeth-
oprim-sulphamethoxazole and tetracycline. Both telithro-
mycin and levofloxacin had good activity against these
Table 2: Distribution of specimen types by species for the 3043 bacterial pathogens described in this study
Specimen S. pneumoniae H. influenzae M. catarrhalis S. aureus H. parainfluenzae1 Total [n (%)]
Sputum 832 895 492 219 43 2481 (81.5)
BAL2 144 135 44 66 17 406 (13.4)
Blood 9 9 705 0 01 5 6  ( 5 . 1 )
Total [n (%)] 1075 (35.3) 1037 (34.1) 536 (17.6) 335 (11.0) 60 (2.0) 3043 (100)
1Only isolated in the first year of the study
2Bronchoalveolar lavageAnnals of Clinical Microbiology and Antimicrobials 2005, 4:5 http://www.ann-clinmicrob.com/content/4/1/5
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Table 3: In vitro activity of antibacterial agents against 3043 bacterial pathogens isolated from patients with AECB and % 
susceptibilities to antibacterial agents.
Organism Antibacterial MIC mg/l % susceptible
range 50 90 total MSSA MRSA
S. pneumoniae N = 1075 Telithromycin 0.004–2 0.015 0.12 99.9
Azithromycin 0.03->64 0.12 >64 71.2
Clarithromycin 0.015->32 0.03 >32 71
Erythromycin 0.03->64 0.06 >64 71
Penicillin 0.008–8 0.03 2 75.3
Amox/clavulanate1 0.015–8 0.03 2 96.1
Cefuroxime 0.015–16 0.03 2 82.2
Trimethoprim-sulphamethoxazole 0.12–32 0.25 8 62
Tetracycline 0.12–32 0.25 32 69.6
Levofloxacin 0.5->32 1 1 98.9
H. influenzae N = 1037 Telithromycin 0.002–16 1 2 99.6
Azithromycin 0.06–32 1 2 99.7
Clarithromycin 0.25->64 8 16 82.4
Erythromycin 0.25->64 4 8 -2
Ampicillin 0.12–32 0.25 16 87.3
Amox/clavulanate1 0.12–4 0.5 1 100
Cefuroxime 0.12–16 1 2 99.5
Trimethoprim-sulphamethoxazole 0.03–32 0.06 4 80.7
Tetracycline 0.12–32 0.5 1 97.4
Levofloxacin 0.008–8 0.015 0.015 99.8
M. catarrhalis N = 536 Telithromycin 0.004–0.5 0.06 0.12
Azithromycin 0.06–0.25 0.06 0.06
Clarithromycin 0.25–0.5 0.25 0.25
Erythromycin 0.25–1 0.25 0.25
Ampicillin 0.12–32 8 16
Amox/clavulanate1 0.12–0.5 0.12 0.25
Cefuroxime 0.12–16 1 2
Trimethoprim-sulphamethoxazole 0.06–4 0.25 0.5
Tetracycline 0.12–32 0.25 0.5
Levofloxacin 0.008–0.06 0.03 0.03
S. aureus N = 335 Telithromycin 0.03->32 0.06 >32 85.1 98.9 24.2
Azithromycin 0.12->64 1 >64 70.4 84.2 9.7
Clarithromycin 0.03->32 0.25 >32 70.4 84.2 9.7
Erythromycin 0.12->64 0.25 >64 70.4 84.6 9.7
Penicillin 0.008–8 4 8 23.6 28.9 0
Amox/clavulanate1 0.06–8 0.5 8 83.1 100 0
Cefuroxime 0.12–16 1 16 81.2 100 0
Trimethoprim-sulphamethoxazole 0.12–32 0.12 0.25 94.9 97.4 83.9
Tetracycline 0.12–32 0.5 32 84.8 92.7 50
Levofloxacin 0.5–64 0.5 8 76.7 81.7 6.5
H. parainfluenzae N = 60 Telithromycin 0.06–4 1 2 100
Azithromycin 0.06–2 0.5 1 100
Clarithromycin 0.25–16 4 8 93.3
Erythromycin 0.5–8 2 4 -2
Ampicillin 0.12–32 0.25 1 90
Amox/clavulanate1 0.12–2 0.5 1 100
Cefuroxime 0.12–4 0.25 0.5 100
Trimethoprim-sulphamethoxazole 0.03–32 0.03 1 88.3
Tetracycline 0.12–16 0.5 4 88.3
Levofloxacin 0.008–8 0.015 0.06 98.4
1Amox/clavulanate = Amoxycillin/clavulanate
2No CLSI interpretive criteria for erythromycin and Haemophilus spp.Annals of Clinical Microbiology and Antimicrobials 2005, 4:5 http://www.ann-clinmicrob.com/content/4/1/5
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isolates, 99% susceptibility to telithromycin and 98.1% to
levofloxacin. The MIC50 and MIC90 values for telithromy-
cin in this population were 0.06 mg/L and 0.5 mg/L,
respectively.
Over 99% of H. influenzae isolates were susceptible to
amoxycillin-clavulanate, cefuroxime, telithromycin, azi-
thromycin, and levofloxacin. Tetracycline also had good
activity with 97.4% of isolates susceptible. Only 11.7% of
H. influenzae isolates produced β -lactamase. There were
only 60 isolates of H. parainfluenzae and 100% of these
were susceptible to four of the eight compounds tested,
telithromycin, amoxycillin/clavulanate, cefuroxime and
azithromycin. Trimethoprim-sulphamethoxazole and tet-
racycline were the least active compounds. In terms of
MICs, levofloxacin, azithromycin and telithromycin were
the most potent compounds against M. catarrhalis with
MIC90  values of 0.03 mg/l, 0.06 mg/l and 0.12 mg/l
respectively.
There are currently no interpretative NCCLS guidelines
available for M. catarrhalis to allow classification into sus-
ceptible or resistant categories.
The total number of isolates of S. aureus was 335 and of
these only 62 were resistant to methicillin (MRSA). Tri-
methoprim-sulphamethoxazole was the most active com-
pound overall, with 94.9% of all isolates being
susceptible. Telithromycin and tetracycline were the next
most active with 85.1% and 84.8% of all isolates
susceptible. Telithromycin was the most active compound
against the MSSA isolates, with 98.9% being susceptible.
The susceptibility of MSSA to tetracycline and trimetho-
prim-sulphamethoxazole was 92.7% and 97.4% suscepti-
ble respectively. These three compounds were the only
ones to have activity against the MRSA isolates (trimetho-
prim-sulphamethoxazole 83.9%, tetracycline 50% and
telithromycin 24.2%). Less than 10% of the MRSA iso-
lates were susceptible to the remainder of the compounds.
Discussion
The primary cause of COPD is exposure to tobacco smoke,
the major risk factor being cigarette smoking. The demog-
raphy of the disease in this study and others reflects this,
as the majority of patients in this analysis were male and
half were elderly (>64 yrs of age) (2). S. pneumoniae is
most frequently isolated in the least severe cases of AECB,
whereas H. influenzae is more commonly isolated from
moderate to severe cases, with P. aeruginosa occurring in
severe hospitalised cases [28]. Telithromycin does not
have good activity against Pseudomonas spp. (GR Micro
Limited, data on file, internal report number 141-02-99)
and hence may not be an appropriate empirical therapeu-
tic option for AECB patients with severe underlying dis-
ease who are hospitalized for an acute exacerbation.
Whether the isolation of a pathogen during AECB repre-
sents an infection responsible for the exacerbation has
been debated for many years [29-31]. Bacteria have been
isolated almost as frequently from patients with stable
COPD as those with an AECB, and clinical trials of antibi-
otic therapy in AECB show contradictory and sometimes
unconvincing results [30]. The presence of bacteria in the
lower airways is, however, regarded as abnormal since
these airways are sterile in healthy adults, and it has been
hypothesized that the presence of bacteria in stable COPD
represents a low-grade smouldering infection. In addi-
tion, a recent study has shown that infection with differ-
ent strains of pathogens that are new to the patient is
associated with development of exacerbation [32,33].
Amoxycillin-clavulanate, azithromycin, and levofloxacin
have been shown to be effective in the treatment of AECB,
however, there is concern regarding their long-term use-
fulness, because of the development of resistance to these
Table 4: Antibacterial activity against 103 Streptococcus pneumoniae isolates with combined macrolide and penicillin resistance
Antibacterial % susceptible % intermediate % resistant
Telithromycin 99.0 1.0 0.0
Azithromycin 0 0 100
Clarithromycin 0 0 100
Erythromycin 0 0 100
Penicillin 0 0 100
Amoxycillin 0 0 100
Amoxycillin-clavulanate 72.8 13.6 13.6
Cefuroxime 1.0 1.0 98.0
Trimethoprim-sulphamethoxazole 19.4 16.5 64.1
Tetracycline 11.7 0.0 88.3
Levofloxacin 98.1 0.0 1.9Annals of Clinical Microbiology and Antimicrobials 2005, 4:5 http://www.ann-clinmicrob.com/content/4/1/5
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agents among the causative pathogens [34,35]. Telithro-
mycin has a more focused spectrum of activity than the β -
lactams and the fluoroquinolones; it is specifically tar-
geted against pathogens causing community-acquired res-
piratory disease, including those most commonly
associated with AECB. In addition, it is active against pen-
icillin- and macrolide-resistant strains of S. pneumoniae
and hence offers a viable potential option for the empiric
treatment of AECB in non-hospitalised patients [36].
The data in this study demonstrate that telithromycin has
high in vitro activity against the commonest bacterial path-
ogens causing AECB. These data also show that telithro-
mycin has the highest overall activity against bacterial
isolates from patients with AECB, regardless of species.
Almost 10% of S. pneumoniae isolated were resistant to
penicillin, macrolides, and at least one of the other antibi-
otics tested, with only telithromycin and levofloxacin
retaining high activity against these isolates (99.0% and
98.1%, respectively). The validity of this finding is
strengthened as the isolates were obtained from a large
number of patients over a wide geographical distribution.
Although atypical pathogens were not examined in the
PROTEKT study, telithromycin has been shown to have
superior activity in vitro against Chlamydophila pneumoniae
to the other macrolides with the exception of clarithromy-
cin and has similar activity to the fluoroquinolones [37].
In guinea pig models, telithromycin had better activity
than erythromycin against Legionella pneumophila infec-
tions [38]. In vitro, the activity of telithromycin against L.
pneumophila was similar to levofloxacin but better than
erythromycin [38]. β -lactams and cephalosporins have no
activity against Mycoplasma pneumoniae as this species
lacks a typical bacterial cell wall, the site of activity for
these drugs. Telithromycin has been found to have higher
activity than doxycycline and levofloxacin against M.
pneumoniae [39]. As the atypical pathogens can represent
up to 10% of infections associated with AECB, the efficacy
of telithromycin against these pathogens could be a con-
sideration in the selection of empiric therapy for AECB.
Telithromycin has been shown to penetrate into respira-
tory tissues well [40]. The concentration of telithromycin
in alveolar macrophages and epithelial lining fluid
exceeds that of plasma markedly and remains at
therapeutic levels for 24 hours after dosing. Bactericidal
levels are also maintained in plasma. A good post-antibi-
otic effect has also been observed [41]. Telithromycin
causes only moderate ecological disturbance to oral and
intestinal flora comparable to that associated with
clarithromycin and it does not significantly increase the
development of resistance in the normal flora, although
the MIC of oral streptococci can be slightly raised [42].
Telithromycin can be administered once a day for AECB.
Clinical studies have demonstrated that 800 mg adminis-
tered once daily for 5 days was as effective and well toler-
ated as a 10-day course of amoxycillin/clavulanate (500/
125 mg 3 times daily for 10 days), cefuroxime axetil (500
mg twice daily for 10 days) or clarithromycin (500 mg
twice daily for 10 days) [43]. Other clinical studies have
also confirmed the safety and tolerability of telithromycin
800 mg administered for 5 – 10 days [44]. Once a day dos-
ing schedules and shorter courses may promote patient
adherence to therapy, and this in turn could delay the
development of resistance.
Although this study provides valuable information on the
overall antimicrobial profile of bacteria causing AECB,
care should be taken when interpreting data related to
specific demographics. The prevalence of species could
not be calculated in this study as a major limitation,
inherent to most surveillance studies, is the requirement
for collecting centres to fulfil a specified quota of isolates
over a defined time period (1 year). If, for instance, a cen-
tre managed to fulfil the quota for S. pneumoniae isolates
from patients with community-acquired pneumonia, it
could then only send H. influenzae from patients with
AECB to fulfil the quota for this organism. In addition,
atypical pathogens were not sampled and they can repre-
sent up to 10% of the causative pathogens [28].
In summary, the data presented here demonstrate that tel-
ithromycin has good in vitro activity against H. influenzae,
S. pneumoniae, and M. catarrhalis, respiratory pathogens
commonly isolated in AECB. It is as active as or more
active than agents that are currently used in this clinical
setting. Additionally, although not shown here, telithro-
mycin has better in vitro activity against atypical patho-
gens than other agents; an important advantage in this
clinical setting as these pathogens may represent 10% of
AECB associated infections.
The development of resistance will always be a threat to
the usefulness of antibacterial compounds, however sur-
veillance studies such as PROTEKT allow the rapid detec-
tion and characterization of resistance mechanisms and
highlight the need for and examine the in vitro efficacy of
newer antibacterial agents. Providing careful surveillance
for the development of resistance is maintained, telithro-
mycin currently offers a useful agent in the treatment of
AECB.
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